302 related articles for article (PubMed ID: 24696867)
21. Estimation of amyloid distribution by [
Thal DR; Beach TG; Zanette M; Lilja J; Heurling K; Chakrabarty A; Ismail A; Farrar G; Buckley C; Smith APL
Acta Neuropathol; 2018 Oct; 136(4):557-567. PubMed ID: 30123935
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic impact of [
Zwan MD; Bouwman FH; Konijnenberg E; van der Flier WM; Lammertsma AA; Verhey FR; Aalten P; van Berckel BN; Scheltens P
Alzheimers Res Ther; 2017 Jan; 9(1):2. PubMed ID: 28093088
[TBL] [Abstract][Full Text] [Related]
23. Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease.
Drzezga A; Grimmer T; Henriksen G; Stangier I; Perneczky R; Diehl-Schmid J; Mathis CA; Klunk WE; Price J; DeKosky S; Wester HJ; Schwaiger M; Kurz A
Neuroimage; 2008 Jan; 39(2):619-33. PubMed ID: 17962045
[TBL] [Abstract][Full Text] [Related]
24. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism.
Rowe CC; Ackerman U; Browne W; Mulligan R; Pike KL; O'Keefe G; Tochon-Danguy H; Chan G; Berlangieri SU; Jones G; Dickinson-Rowe KL; Kung HP; Zhang W; Kung MP; Skovronsky D; Dyrks T; Holl G; Krause S; Friebe M; Lehman L; Lindemann S; Dinkelborg LM; Masters CL; Villemagne VL
Lancet Neurol; 2008 Feb; 7(2):129-35. PubMed ID: 18191617
[TBL] [Abstract][Full Text] [Related]
25. Astrocytosis precedes amyloid plaque deposition in Alzheimer APPswe transgenic mouse brain: a correlative positron emission tomography and in vitro imaging study.
Rodriguez-Vieitez E; Ni R; Gulyás B; Tóth M; Häggkvist J; Halldin C; Voytenko L; Marutle A; Nordberg A
Eur J Nucl Med Mol Imaging; 2015 Jun; 42(7):1119-32. PubMed ID: 25893384
[TBL] [Abstract][Full Text] [Related]
26. Infrequent false positive [
Ikonomovic MD; Fantoni ER; Farrar G; Salloway S
Alzheimers Res Ther; 2018 Jun; 10(1):60. PubMed ID: 29935545
[TBL] [Abstract][Full Text] [Related]
27. Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease.
Kadir A; Marutle A; Gonzalez D; Schöll M; Almkvist O; Mousavi M; Mustafiz T; Darreh-Shori T; Nennesmo I; Nordberg A
Brain; 2011 Jan; 134(Pt 1):301-17. PubMed ID: 21149866
[TBL] [Abstract][Full Text] [Related]
28. Amyloid PET Imaging: Standardization and Integration with Other Alzheimer's Disease Biomarkers.
Morbelli S; Bauckneht M
Methods Mol Biol; 2018; 1750():203-212. PubMed ID: 29512074
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of [¹⁸F]flutemetamol in wild-type rodents and its binding to beta amyloid deposits in a mouse model of Alzheimer's disease.
Snellman A; Rokka J; Lopez-Picon FR; Eskola O; Wilson I; Farrar G; Scheinin M; Solin O; Rinne JO; Haaparanta-Solin M
Eur J Nucl Med Mol Imaging; 2012 Nov; 39(11):1784-95. PubMed ID: 22801729
[TBL] [Abstract][Full Text] [Related]
30. Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation.
Villeneuve S; Rabinovici GD; Cohn-Sheehy BI; Madison C; Ayakta N; Ghosh PM; La Joie R; Arthur-Bentil SK; Vogel JW; Marks SM; Lehmann M; Rosen HJ; Reed B; Olichney J; Boxer AL; Miller BL; Borys E; Jin LW; Huang EJ; Grinberg LT; DeCarli C; Seeley WW; Jagust W
Brain; 2015 Jul; 138(Pt 7):2020-33. PubMed ID: 25953778
[TBL] [Abstract][Full Text] [Related]
31. Positron emission tomography with [18F]flutemetamol and [11C]PiB for in vivo detection of cerebral cortical amyloid in normal pressure hydrocephalus patients.
Leinonen V; Rinne JO; Virtanen KA; Eskola O; Rummukainen J; Huttunen J; von Und Zu Fraunberg M; Nerg O; Koivisto AM; Rinne J; Jääskeläinen JE; Buckley C; Smith A; Jones PA; Sherwin P; Farrar G; McLain R; Kailajärvi M; Heurling K; Grachev ID
Eur J Neurol; 2013 Jul; 20(7):1043-52. PubMed ID: 23398333
[TBL] [Abstract][Full Text] [Related]
32. Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density.
Curtis C; Gamez JE; Singh U; Sadowsky CH; Villena T; Sabbagh MN; Beach TG; Duara R; Fleisher AS; Frey KA; Walker Z; Hunjan A; Holmes C; Escovar YM; Vera CX; Agronin ME; Ross J; Bozoki A; Akinola M; Shi J; Vandenberghe R; Ikonomovic MD; Sherwin PF; Grachev ID; Farrar G; Smith AP; Buckley CJ; McLain R; Salloway S
JAMA Neurol; 2015 Mar; 72(3):287-94. PubMed ID: 25622185
[TBL] [Abstract][Full Text] [Related]
33. Clinical impact of [
Leuzy A; Savitcheva I; Chiotis K; Lilja J; Andersen P; Bogdanovic N; Jelic V; Nordberg A
Eur J Nucl Med Mol Imaging; 2019 Jun; 46(6):1276-1286. PubMed ID: 30915522
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum.
Murray ME; Lowe VJ; Graff-Radford NR; Liesinger AM; Cannon A; Przybelski SA; Rawal B; Parisi JE; Petersen RC; Kantarci K; Ross OA; Duara R; Knopman DS; Jack CR; Dickson DW
Brain; 2015 May; 138(Pt 5):1370-81. PubMed ID: 25805643
[TBL] [Abstract][Full Text] [Related]
35. Development of a PET/SPECT agent for amyloid imaging in Alzheimer's disease.
Wang Y; Klunk WE; Debnath ML; Huang GF; Holt DP; Shao L; Mathis CA
J Mol Neurosci; 2004; 24(1):55-62. PubMed ID: 15314250
[TBL] [Abstract][Full Text] [Related]
36. Characterization and first human investigation of FIBT, a novel fluorinated Aβ plaque neuroimaging PET radioligand.
Yousefi BH; Manook A; Grimmer T; Arzberger T; von Reutern B; Henriksen G; Drzezga A; Förster S; Schwaiger M; Wester HJ
ACS Chem Neurosci; 2015 Mar; 6(3):428-37. PubMed ID: 25482310
[TBL] [Abstract][Full Text] [Related]
37. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study.
Barthel H; Gertz HJ; Dresel S; Peters O; Bartenstein P; Buerger K; Hiemeyer F; Wittemer-Rump SM; Seibyl J; Reininger C; Sabri O;
Lancet Neurol; 2011 May; 10(5):424-35. PubMed ID: 21481640
[TBL] [Abstract][Full Text] [Related]
38. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial.
Vandenberghe R; Van Laere K; Ivanoiu A; Salmon E; Bastin C; Triau E; Hasselbalch S; Law I; Andersen A; Korner A; Minthon L; Garraux G; Nelissen N; Bormans G; Buckley C; Owenius R; Thurfjell L; Farrar G; Brooks DJ
Ann Neurol; 2010 Sep; 68(3):319-29. PubMed ID: 20687209
[TBL] [Abstract][Full Text] [Related]
39. An in vivo evaluation of cerebral cortical amyloid with [18F]flutemetamol using positron emission tomography compared with parietal biopsy samples in living normal pressure hydrocephalus patients.
Wong DF; Moghekar AR; Rigamonti D; Brašić JR; Rousset O; Willis W; Buckley C; Smith A; Gok B; Sherwin P; Grachev ID
Mol Imaging Biol; 2013 Apr; 15(2):230-7. PubMed ID: 22878921
[TBL] [Abstract][Full Text] [Related]
40. Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG.
Shin J; Lee SY; Kim SJ; Kim SH; Cho SJ; Kim YB
Neuroimage; 2010 Aug; 52(2):488-96. PubMed ID: 20385246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
